The synergistic action of ALA and SOD improves both nerve conduction velocity and perceived

pain, stating few or absent side effects of this formulation and of the two single components already confirmed by clinical and postmarketing surveillance.[17,30] SOD prevents the formation of free radicals and ALA promotes their removal; furthermore, the oral formulation (with improved bioavailability) improves the patient’s quality of life, removing the burden of infusion therapy. In addition, this neurotrophic integrator shows clinically MDV3100 cost relevant results over a brief time period with homogeneous improvements amongst patients. We report the https://www.selleckchem.com/products/gsk1120212-jtp-74057.html present study as a clinical experience because we chose a per protocol analysis to maximize the opportunity for the proposed treatment to show its efficacy and the actual number of enrolled patients was relatively small as a prospective study. Capmatinib cost Further studies (e.g. a phase III, multicenter trial with a group treated

with ALA and SOD vs a group treated with placebo) are warranted to support our results with a greater sample size and to investigate placebo effects and longer follow-up for duration of response and for treatment safety. Furthermore, future research should quantify the added value of SOD over ALA. Conclusion Our study is the first to show that treatment with a combination of ALA and SOD leads to an improvement both in symptomatology and in electroneurographic parameters in patients affected by DN. The results suggest a new scenario for the management of DN, a new non-invasive treatment Edoxaban with no registered adverse events. This pivotal study indicates future directions for useful investigation. Acknowledgements No sources of funding were used in the study design, collection, analysis, or interpretation of the data, or in writing this article. The authors declare that they have no conflicts of interest to disclose. References 1. Mijnhout GS, Alkhalaf A, Kleefstra N, et al. Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes? Neth J Med 2010; 68 (4): 158–62PubMed 2. Van Acker K, Bouhassire D, De Bacquer D, et al.

Prevalence and impact on quality of life of peripheral neuropathy with or without neuropatic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009; 35: 206–13PubMedCrossRef 3. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956–62PubMedCrossRef 4. Vallianou N, Evangelopoulos A, Koutalas P. Alpha-lipoic acid and diabetic neuropathy. Rev Diabet Stud 2009; 6 (4): 230–6PubMedCrossRef 5. Daousi C, Benbow SJ, Woodward A, et al. The natural history of chronic painful peripheral neuropathy in a community diabetes population. Diabet Med 2006; 23: 1021–4PubMedCrossRef 6. Davies M, Brophy S, Williams R, et al.